Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

103.76 -1.47 (-1.40%)

Streaming Delayed Price Updated: 1:32 PM EDT, Sep 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

57 58 Next >

Healthcare And Life Science Funds And ETFs Performance 2023-2024 ↗

February 05, 2024

Healthcare stocks usually provide a defensive posture to a stock portfolio.

Via Talk Markets

Topics ETFs

2 Stocks to Buy Near Their 52-Week Highs ↗

February 05, 2024

It's not too late to invest in these stocks.

Via The Motley Fool

2 Healthcare Dividend Kings to Buy and Hold Forever ↗

February 04, 2024

It's going to take a lot to interrupt these companies' streaks.

Via The Motley Fool

Abbott Faces Lawsuit As Grandmother Questions PediaSure's Height Growth Claims ↗

February 03, 2024

Abbott Laboratories faces a lawsuit questioning the efficacy of PediaSure Grow & Gain nutrition drinks in promoting height growth.

Via Benzinga

Topics Lawsuit

Is Abbott Laboratories Stock a Buy Now? ↗

February 03, 2024

Can Abbott Laboratories be a reliable income stock to hang on to now?

Via The Motley Fool

Could Abbott Labs Be the Next Big Winner in the Billion-Dollar Weight Loss Market? ↗

February 02, 2024

Abbott Labs is using its well-established strengths to make gains in the weight loss market.

Via The Motley Fool

Looking At Abbott Laboratories's Recent Unusual Options Activity ↗

January 30, 2024

Via Benzinga

Looking Into Abbott Laboratories's Recent Short Interest ↗

January 26, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Abbott Laboratories ↗

January 25, 2024

Via Benzinga

4 med tech stocks with improving prognosis for 2024

January 31, 2024

MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025.

Via MarketBeat

7 ‘AgeTech’ Stocks to Profit From the Booming Longevity Market ↗

January 28, 2024

Aging is an inevitability, as much as we try to deny it. Under this context, these AgeTech stocks may prove quite relevant.

Via InvestorPlace

Stock Market Continues To Rally; ASML, Netflix, Tesla, Intel Are Big Earnings Movers: Weekly Review ↗

January 26, 2024

The S&P 500 and Dow Jones hit fresh record highs on Friday.

Via Investor's Business Daily

Topics Stocks

Earnings Preview For Abbott Laboratories ↗

January 23, 2024

Via Benzinga

World's Smallest Brain Stimulation Device For Movement Disorder: FDA Approved Abbott's Liberta RC DBS system ↗

January 25, 2024

Abbott's Liberta RC DBS system, the world's smallest FDA-approved rechargeable deep brain stimulation device. With only 10 recharges a year, it's compatible with NeuroSphere Virtual Clinic, reducing...

Via Benzinga

Abbott Laboratories on track for new highs in 2024

January 25, 2024

Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact.

Via MarketBeat

Stock Market Extends Record Highs, S&P 500 Hits 4,900 On Tech Rally, Microsoft's $3 Trillion Mark: What's Driving Markets Wednesday? ↗

January 24, 2024

It’s a bullish day on Wall Street, with major U.S. large-cap indices reaching record highs, driven by broad-based rallies in tech-related stocks as investors continue to embrace the AI trade.

Via Benzinga

Topics Artificial Intelligence Stocks

Abbott Laboratories (ABT) Q4 2023 Earnings Call Transcript ↗

January 24, 2024

ABT earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Abbott Laboratories Surpasses Q4 Sales Expectations, Despite Dip In COVID-19 Testing Demand ↗

January 24, 2024

Abbott Laboratories exceeds expectations with Q4 sales of $10.24B, showcasing resilience despite softer demand for COVID-19 testing. CEO anticipates continued growth in 2024.

Via Benzinga

Abbott Labs Skids On Light Earnings Guidance Despite Quarterly Sales Beat ↗

January 24, 2024

Abbott beat sales expectations and earnings came in light for the fourth quarter.

Via Investor's Business Daily

Abbott Laboratories Barely Hits Q4 Target With $1.19 EPS ↗

January 24, 2024

Abbott Laboratories announces Q4 results with $10.24 billion in revenue and an EPS of $1.19.

Via Talk Markets

Nasdaq, S&P 500 Futures Jump As Wall Street Eagerly Awaits Tesla's Q4 Earnings: Analyst Says Rally Broadening But Favors These Stocks ↗

January 24, 2024

Earnings have served to mitigate early January's weakness, and sentiment appears to be upbeat going into Wednesday's session.

Via Benzinga

Topics Stocks

Earnings Scheduled For January 24, 2024 ↗

January 24, 2024

Companies Reporting Before The Bell • Freeport-McMoRan (NYSE:FCX) is estimated to report quarterly earnings at $0.22 per share on revenue of $5.86 billion.

Via Benzinga

Investor Optimism Improves Following Earnings Reports; S&P 500 Reaches Another High ↗

January 24, 2024

The CNN Money Fear and Greed index showed a further increase in overall market sentiment, while the index remained in the "Greed" zone on Tuesday. U.S. stocks closed mixed on Tuesday, with the Dow...

Via Benzinga

Topics Stocks

Netflix, Tesla And 3 Stocks To Watch Heading Into Wednesday ↗

January 24, 2024

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst ↗

January 23, 2024

Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.

Via Benzinga

7 Safe-Haven Stocks to Protect Your Portfolio During a Recession ↗

January 23, 2024

We may not be out of the woods yet, which means certain stable enterprises should be on your radar.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 23, 2024

Via Benzinga

Johnson & Johnson's stock price is at a critical turning point

January 23, 2024

Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech.

Via MarketBeat

Topics Intellectual Property

Top Stocks To Watch As Earnings Approach ↗

January 23, 2024

Several expansive companies are expected to post stellar quarterly growth when they report Q4 earnings on Wednesday, January 24. Here are a few top-rated stocks to consider as their quarterly results...

Via Talk Markets

S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday? ↗

January 22, 2024

US stocks rise to record highs on strong earnings reports, with small caps outperforming. Dollar steady, gold down, oil up. Bitcoin tumbles. AMD, TSLA, ADM, GILD, WDC top movers. GE, AAPL, FB, AMZN,...

Via Benzinga

Topics Stocks

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.